ShockWave Medical, Inc.
SWAV · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.42 | -0.01 | 7.88 | 7.45 |
| FCF Yield | 2.37% | 1.25% | 0.04% | -2.41% |
| EV / EBITDA | 42.17 | 57.11 | -7,137.81 | -54.66 |
| Quality | ||||
| ROIC | 9.57% | 38.00% | -0.30% | -26.23% |
| Gross Margin | 86.94% | 86.73% | 82.53% | 69.03% |
| Cash Conversion Ratio | 1.33 | 0.55 | -1.65 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 45.48% | 93.32% | 76.78% | 76.82% |
| Free Cash Flow Growth | 78.67% | 3,465.88% | 103.14% | -59.28% |
| Safety | ||||
| Net Debt / EBITDA | 2.51 | -0.75 | 48.24 | 0.41 |
| Interest Coverage | 26.79 | 65.82 | -0.79 | -54.18 |
| Efficiency | ||||
| Inventory Turnover | 0.89 | 0.87 | 0.96 | 0.70 |
| Cash Conversion Cycle | 435.00 | 437.25 | 405.18 | 556.65 |